

ESSKA survey on Prophylaxis for Venous Thromboembolism (VTE) in Hip Arthroscopy

Thursday, July 27, 2017


52

Total Responses

Date Created: Tuesday, May 30, 2017


Complete Responses: 52

Q: VTE prophylaxis is an important clinical consideration in hip arthroscopy:




Answer Choices	Responses
Strongly Agree	36.54%
Agree	36.54%
Neutral	9.62%
Disagree	11.54%
Strongly Disagree	5.77%

Q: How many years of experience in hip arthroscopy do you have?




Answer Choices	Responses
0-5	42.31%
6-10	23.08%
11-15	26.92%
16-20	5.77%
>20	1.92%

Q: How many hip arthroscopies do you perform per year?




Answer Choices	Responses
<25	28.85%
26-50	26.92%
51-100	23.08%
101-200	15.38%
>200	5.77%

Q: Which is the percentage of your hip arthroscopy patients who receive VTE prophylaxis?




Answer Choices	Responses
None	5.77%
<10%	26.92%
10%-50%	5.77%
51%-75%	0.00%
76%-99%	9.62%
100%	51.92%

Q: If you don't perform Systematic VTE prophylaxis, which risk factors do you consider deciding for VTE prophylaxis? (more than one answer allowed)




Answer Choices	Response
Previous VTE or familiarity for VTE	91.43%
Known predisposing genetic disorders	80.00%
Use of oral contraceptives	60.00%
Postoperative reduced weight bearing	28.57%
Longer /complicated Hip arthroscopy	40.00%
Smoke habits	45.71%
Other	8.57%

Q: How long do you continue VTE prophylaxis?(more than one answer allowed)




Answer Choices	Response
< 7 days	7.84%
7 days	23.53%
8-15 days	47.06%
16-35 days	21.57%
Variable based on weight bearing status	15.69%

Q8 Which kind of VTE prophylaxis do you usually prefer to administer?




Answer Choices	Responses
Pharmacological	68.63%
Mechanical	1.96%
Combined (pharmacological+ mechanical)	29.41%
Other (enter here)	0.00%
None	0.00%

Q: In case of VTE pharmacological prophylaxis, which is your first choice?




Answer Choices	Responses
LMWH (low molecular weight heparin)	78.85%
Acetylsalicylic acid (ASA)	5.77%
Vitamin K antagonists (VKA)	1.92%
New oral anticoagulants (NOA)	13.46%
Fondaparinux (FON)	0.00%
Other	0.00%

Q: In case of VTE pharmacological prophylaxis, which other drug have you used?




Answer Choices	Responses
LMWH (low molecular weight heparin)	35.71%
Acetylsalicylic acid (ASA)	23.81%
Vitamin K antagonists (VKA)	2.38%
New oral anticoagulants (NOA)	33.33%
Fondaparinux (FON)	4.76%

Q: In case of mechanical prophylaxis, which?




Answer Choices	Responses
Graduated compression stockings (GCS)	68.75%
Intermittent pneumatic compression (IPC) devices	15.63%
Both	9.38%
Other	6.25%

Q: What is the Deep Venous Thrombosis (DVT) rate in your clinical experience?




Answer Choices	Responses
Unknown	19.61%
0	29.41%
<1%	37.25%
1%-2%	9.80%
3%-5%	3.92%
6%-8%	0.00%
>8%	0.00%

Q: Which is the Pulmonary Embolus (PE) rate in your clinical experience?




Answer Choices	Responses
Unknown	13.46%
0	57.69%
<0,1%	17.31%
0,1%-0,2%	9.62%
0,3%-0,5%	1.92%
>0,5%	0.00%

Q: The potential for complications with the use of pharmacological or mechanical prophylaxis affect my choice of VTE prophylaxis:



Answer Choices	Responses
Strongly Agree	19.61%
Agree	29.41%
Neutral	17.65%
Disagree	27.45%
Strongly Disagree	5.88%

Q: Which VTE prophylaxis consequence or consideration impacts your choice of prophylaxis?(more than one answer allowed)



Answer Choices	Responses
Bleeding	66.00%
Other drug related adverse events	42.00%
Patient's compliance/wishes	44.00%
Cost	26.00%
Method of administration	22.00%
Others	6.00%